Evidence map›Paper›PMID 38107066›Full record

ArticleFrontiers in oncology2023

Treatment for a primary multidrug-resistant B-cell acute lymphoblastic leukemia patient carrying a SSBP2-CSF1R fusion gene: a case report.

Huan Wang, Yujiao Wang, Liangchun Hao, Xuan Liu, Jihong Zhang, Pin Yao, Danping Liu, Runan Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Huan WangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Yujiao WangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Liangchun HaoDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xuan LiuDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Jihong ZhangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Pin YaoDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Danping LiuPrecision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.
Runan WangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
China Medical University · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SSBP2-CSF1R is an important biomarker for clinical diagnosis and prognosis of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). This case report presents a pediatric Ph-like ALL patient carrying the SSBP2-CSF1R fusion gene. The patient was resistant to most conventional chemotherapy regimens and to dasatinib, an inhibitor that has been reported to have a therapeutic effect on SSBP2-CSF1R fusion Ph-like ALL, as she remained minimal residual disease (MRD) positive (detection by flow cytometry) and SSBP2-CSF1R fusion gene (detection by RT-PCR) positive after five rounds of such regimens. We thus conducted a large-scale

Indexed as

childrenMRDmultidrug resistancePhiladelphia chromosome-like acute lymphoblastic leukemiaSSBP2-CSF1R fusion

Identifiers

PMID38107066
PMCPMC10723836
OpenAlexW4389204193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.